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Approximately 1.0–1.5% of the genome is transcriptionally regulated by hypoxia, and hypoxia-inducible factor (HIF)-1α is the 
transcription factor modulating many of these genes. Cancer cells are able to survive hypoxic environments and hypoxia itself can 
activate adaptive cellular responses that contribute to tumor progression. Many HIF-1α-mediated biological effects are beneficial 
for tumor progression, including metabolic shift toward glycolysis, inhibition of fatty acid β-oxidation, production of cellular reac-
tive oxygen species and altering expression of tumor suppressor genes. HIF-1 promotes selective mitochondrial autophagy, resis-
tance to T cell mediated lysis of cancer cells, induction of pluripotent cancer stem cells, epithelial-mesenchymal and epithelial-
mesenchymal-endothelial transitions beneficial for tumor growth and progression, loss of E-cadherin. HIF-1 also induces produc-
tion of signal molecules and cytokines by carcinoma-associated fibroblasts and upregulation of certain microRNAs important for 
cancer progression. This minireview focuses on the HIF-1 promoting role in tumor initiation and progression and HIF-1 targeting. 
HIF-1 pathway downregulation seems to be promising in future cancer treatment.
Key Words: adaptive cellular response, cancer stemness, hypoxia, hypoxia-inducible factor 1, tumor progression.
Hypoxia-inducible factor �HIF�-� plays an essential 
role in cellular and systemic oxygen �omeostasis [�]. 
Approximately �.���.5% of t�e genome is transcrip-
tionally regulated by �ypoxia� and HIF-�α is t�e trans-
cription factor modulating many of t�ese genes [�]. 
Under normoxic conditions� HIF-�α �as a �alf-life 
in cytoplasm of < 5 min� but �ypoxic conditions stabi-
lize HIF-�α� w�ic� escapes degradation and translo-
cates to t�e nucleus [�]. In t�e nucleus� dimerisation 
of HIF-�α wit� HIF-�β under �ypoxic conditions results 
in t�e formation of t�e HIF-� transcription factor� w�ic� 
binds to �ypoxia response elements and activates t�e 
transcription of O�-dependent genes [�]. Insufficient 
oxygen supply produces stressful environments for 
normal cells and can promote cell deat� in �ypoxic 
regions by eit�er apoptosis or necrosis [�].
Poorly vascularized and perfused tumor microar-
eas in many aggressive cancers �ave limited access 
not only to oxygen but also to glucose. Core regions 
are also associated wit� acidic pH since t�ese tumor 
cells c�ange t�eir metabolism towards increased 
glycolysis� resulting in increased lactic acid produc-
tion. Abnormal vascularization of solid tumors results 
in t�e development of microenvironments deprived 
of oxygen and nutrients t�at �arbour slowly growing 
and metabolically stressed cells. Suc� cells display 
en�anced resistance to standard c�emot�erapeutic 
agents and repopulate tumors after t�erapy [4].
Cancer cells are able to survive �ypoxic environ-
ments and �ypoxia itself can activate adaptive cel-
lular responses t�at contribute to tumor progression 
[5]. �any HIF-�α-mediated biological effects are 
ben eficial for tumor progression� including s�ifting 
metabolism toward glycolysis� induction of angiogen-
esis� regulation of apoptosis� induction of migration 
to escape �ostile �ypoxic environments� and t�erapy 
resistance [5� �].
Induction of HIF-�α �as two effects in tumor 
cells: i. HIF-�α triggers t�e p�osp�orylation of Src 
w�ic� subsequently p�osp�orylates t�e tyrosine 
residue Y7�5 of STAT� �signal transducer and activa-
tor of transcription ��; ii. HIF-�α activates autop�agy 
by a mec�anism implicating t�e increased expression 
of BCL�/adenovirus E�B �� kDa protein-interacting 
protein � �BNIP��/BNIP�-like �BNIP�L� and t�e dis-
sociation of t�e beclin �-BCL� �B cell lymp�oma �� 
complex [7].
By upregulating t�e expression of BNIP� and 
BNIP�L� HIF-� promotes selective mitoc�ondrial auto-
p�agy [7]. Autop�agy is typically a stress adaptation 
mec�anism in response to a variety of stress stimuli 
including starvation� �ypoxia� endoplasmic reticulum 
stress� and oxidative stress t�at trigger a pro-survival 
pat�way avoiding cell deat�. In cancer t�erapy� auto-
p�agy is activated as an adaptive response to promote 
cell survival. Autop�agy ensures cell metabolism� 
supplies tumor cell survival and prevents cancer cells 
from accumulating dysfunctions [�]. During cancer 
progression� autop�agy can be induced by different 
stresses� particularly �ypoxia� nutrient deprivation� 
or extracellular matrix detac�ment. Recent evidence 
�as demonstrated t�at tumor cells can escape natural 
killer �NK�-mediated immune surveillance by activating 
autop�agy under �ypoxia [7].
An interesting recent report �as proved t�at lym-
p�oid effectors not only provide lytic signals but also 
promote autop�agy in t�e remaining target cells� 
a process called cell-mediated autop�agy [7]. T�us� 
cell-mediated autop�agy �as been reported in dif-
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ferent �uman epit�elial tumors after interaction wit� 
immune cells at a �ig� ratio of effectors to targets. 
Importantly� it �as been s�own t�at cell-mediated 
autop�agy not only acts as a mec�anism of resistance 
to immune cell-mediated lysis but also limits t�e cyto-
toxic activity of stress factors suc� as γ-radiation [7]. 
BNIP�L and BNIP� also play roles in t�e mediation 
of mitop�agy allowing t�e cells to get rid of dysfunc-
tional mitoc�ondria and promote virus-specific NK cell 
survival during t�e contraction p�ase of t�e response 
to murine cytomegalovirus. It �as implications for t�e 
development of effective antiviral and anticancer treat-
ments� as well as vaccination strategies targeting t�e 
autop�agy pat�way in NK cells [�].
In breast cancer in response to reduced O� avail-
ability� HIF-� mediates t�e transcriptional activation 
of genes encoding proteins t�at are required for many 
important steps in progression� suc� as angiogenesis� 
cancer stem cell �CSC� maintenance� cell motility� 
epit�elial-mesenc�ymal transition �E�T�� extracel-
lular matrix remodeling� metabolic reprogramming� 
metastasis� and resistance to t�erapy [��]. HIF-� binds 
directly to gene encoding t�e transcriptional co-
activator wit� PDZ-binding motif �TAZ�� an effector 
of Hippo signaling. TAZ interacts wit� DNA binding 
proteins to activate transcription of target genes� suc� 
as CTGF �encoding connective tissue growt� factor�� 
w�ic� promote E�T and t�e breast cancer stem-cell 
p�enotype bidirectional functional interactions be-
tween HIF-�α and TAZ t�at synergistically drive t�e 
expression of downstream target genes in �ypoxic 
breast cancer cells [��].
Carcinoma-associated fibroblasts �CAFs� play 
a pivotal role in cancer progression by contributing 
to invasion� metastasis and angiogenesis [��]. Hypoxia 
upregulates HIF-�α� G protein-coupled estrogen re-
ceptor �GPER� and smoot� muscle actin α expression 
in CAFs� and induces t�e secretion of interleukin-�� 
vascular endot�elial growt� factor �VEGF�� and CTGF 
in CAFs [��]. As a biological counterpart of t�ese 
findings� conditioned medium from �ypoxic CAFs 
promotes tube formation in �uman umbilical vein en-
dot�elial cells in a HIF-�α/GPER dependent manner. 
T�e functional cooperation between HIF-�α and GPER 
in CAFs was also evidenced in t�e �ypoxia-induced 
cell migration� w�ic� involves a furt�er target of t�e 
HIF-�α/GPER signaling like CTGF [��].
HIFs may promote a CSC state� w�ereas t�e loss 
of HIFs induces t�e production of cellular reactive 
oxygen species �ROS� and activation of p5� and 
p��INK4A proteins� w�ic� lead to tumor cell deat� and 
senescence. Hypoxic conditions en�ance t�e genera-
tion of induced pluripotent stem cells. During repro-
gramming of somatic cells into a PSC state� cells attain 
a metabolic state typically observed in embryonic stem 
cells. T�e embryonic stem cells and induced pluripo-
tent stem cells s�are similar bioenergetic metabolisms� 
including decreased mitoc�ondrial number and acti-
vity� and induced anaerobic glycolysis [�4].
In tumor� tissue �ypoxia plays a critical role in can-
cer cell maintenance. In particular� Twist� expression 
is directly triggered by HIF-� w�ile t�e transactivation 
function of Twist� �as been implicated in E�T [�5].
CSCs usually represent a small percentage of cells 
residing in a tumor mass. Nevert�eless� since CSCs 
�ave t�e abilities for self-renewal and differentiation 
into secondary tumors� it is believed t�at CSCs are 
responsible for resistance of cancer cells to conven-
tional c�emo-/radiation t�erapy. Recent experimental 
evidence suggests t�at t�e E�T process indeed con-
tributes to stem-like properties of cancer cells [�5].
Since cancer stemness is maintained by HIFs� 
t�e HIF-inducible Twist� may be directly involved 
in regulating expression of stemness genes� promoting 
synergetic E�T� and self-renewal capability. Twist� ac-
tivation provides several advantages to cancer cells. 
At t�e individual cellular level� Twist�-mediated E�T 
en�ances cancer cell ability to move and invade [�5]. 
T�e Twist�-mediated stemness provides cancer cells 
wit� t�e capability of self-renewal and� more impor-
tantly� resistance to conventional anti-cancer c�e-
mot�erapy. At t�e multicellular tumor level� Twist� can 
extend E�T one step furt�er� to t�e epit�elial-mesen-
c�ymal-endot�elial transition. In t�is concept� Twist�-
overexpressing tumor cells can trans-differentiate 
into endot�elial cells and directly contribute to t�e 
angiogenesis process [�5].
T�e recent discovery t�at a subset of cellular 
microRNAs �miRs� are upregulated during �ypoxia� 
w�ere t�ey function to promote tumor development� 
�ig�lig�ts t�e importance of �ypoxia-induced miRs 
as targets for continued investigation. Under �ypoxic 
conditions� miR-��� becomes �ig�ly upregulated in re-
sponse to HIFs. HIF-�α drives miR-��� overexpression 
and t�e resultant alteration of cellular processes� in-
cluding cell cycle regulation� mitoc�ondria function� 
apoptosis� angiogenesis and metastasis [��].
T�e migration of tumor cells is mediated by loss 
of E-cad�erin� w�ic� results in a more invasive p�e-
notype� dissemination of t�e tumor cells by increased 
vascular permeability and survival in t�e bloodstream 
t�roug� resistance to apoptosis as well as ad�esion 
at t�e premetastatic nic�e� all of t�em being controlled 
by factors under t�e influence of HIF-� [�7].
HIF-�α in�ibits fatty acid β-oxidation �FAO� 
by in�ibiting two FAO enzymes� t�e medium-c�ain 
acyl-CoA de�ydrogenase ��CAD� and long-c�ain 
acyl-CoA de�ydrogenase �LCAD� t�at catalyze t�e 
first step of FAO in mitoc�ondria. Bot� �CAD- and 
LCAD-regulated FAO facilitates tumor cell proliferation 
by altering ROS levels and glycolysis. However� defi-
ciency of LCAD-induced unsaturated fatty acid oxida-
tion affects largely cancer progression by regulating 
t�e PTEN pat�way [��] and enabling rapid growt� and 
division of cancer cells.
Recently� Krtolica et al. [��] assayed t�e efficacy 
of O�X-4.��P �long-acting oxygen carrier in circula-
tion and tumor� t�at downregulates HIF-� pat�way 
in intracranial glioblastoma models in nude mice� 
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immunocompetent rats and in spontaneous canine 
brain tumors. T�e preclinical data demonstrate t�at 
�ypoxia reduction and HIF-� pat�way downregulation 
dramatically en�ance response to radiation t�erapy 
leading to tumor cures.
In t�e recent study� ��% of examined ��� invasive 
breast cancers from an African population s�owed 
strong HIF-�α expression� w�ic� was significantly 
associated wit� ot�er factors of poor prognosis like 
VEGF expression and increased angiogenesis� �ig� 
tumor cell proliferation by Ki-�7 rate� p5� expression� 
as well as �ig� �istological tumor grade [��]. Nuclear 
expression of HIF-�α was found in �7% cases of en-
dometrial cancer patients. Hig�er HIF-�α expression 
was associated wit� �ig�er risk of recurrence [��]. 
Immuno�istoc�emical studies demonstrated t�at 4�% 
of examined primary pancreatic cancers were HIF-�α 
positive and t�e status of HIF-�α was significantly cor-
related wit� metastatic status� VEGF expression and 
intratumoral microvessel density [��]. Overexpres-
sion of HIF-�α was found to be an indicator of poor 
prognosis for patients wit� gastric cancer and was 
significantly correlated wit� �istology� dept� of inva-
sion� VEGF� and microvessel density [��� �4].
HIF-�α overexpression was more frequent in pa-
tients wit� �epatic metastases in peritoneal cavity. 
T�e patients wit� HIF-�α overexpression �ad a s�orter 
disease-free survival and overall survival t�an patients 
wit� weak expression [�5]. Hig� HIF-�α expression 
is associated wit� t�e development and progression 
of �epatocellular carcinoma [��]. Oxygen-regulated 
component of HIF-� �HIF-�α� is overexpressed in clus-
ters of leukemic cells in t�e bone marrow specimens 
of c�ild�ood acute lymp�oblastic leukemia �ALL� 
and absent in biopsies of normal bone marrow [�7]. 
Half of HIF-�α-positive ALL biopsies ex�ibited VEGF 
coexpression. In all ALL specimens� HIF-�α immuno-
staining was concentrated primarily wit�in t�e nuclei 
of leukemic cells.
Considering t�e multiple roles of HIF-� in tumor 
progression and metastasis� t�ere �as been great 
interest in developing in�ibitors targeting t�is pat�way. 
�ost of t�e reported HIF-�α in�ibitors were originally 
discovered for targeting ot�er endogenous molecules 
and later t�eir HIF-�α in�ibitory activity was recognized 
t�roug� some empirical testing [��]. In particular� car-
diac glycosides were identified as in�ibitors of HIF-�α. 
Digoxin decreases cell proliferation and viability in liver 
cancer cell line [��].
Cisplatin downregulates t�e level of t�e regulat-
able α subunit of HIF-�� HIF-�α� in cisplatin-sensitive 
ovarian cancer cells t�roug� en�ancing HIF-�α deg-
radation but does not downregulate HIF-�α in t�eir 
cisplatin-resistant counterparts [��]. P�armacological 
promotion of HIF-�α degradation en�ances response 
to cisplatin in bot� cisplatin-sensitive and cisplatin-
resistant ovarian cancer cells. T�ese findings suggest 
t�at t�e HIF-�α-regulated cancer metabolism pat�way 
could be a novel target for overcoming cisplatin resis-
tance in ovarian cancer.
EZN-����� an antisense oligonucleotide against 
HIF-�α� is being tested in a P�ase I clinical trial wit� 
advanced solid tumors [��� ��]. Temsirolimus and 
everolimus �ave passed P�ase III clinical trials and FDA 
approval for treatment of metastatic renal cell carci-
noma [��]. Combination treatment wit� everolimus� 
letrozole and trastuzumab is well tolerated and effec-
tive in estrogen receptor+� HER�+ and/or mutant solid 
tumors� including breast and cervical cancer [��]. 
Everolimus �as already received regulatory approval 
in combination wit� exemestane for t�e treatment 
of aromatase in�ibitor-refractory metastatic �ormone 
receptor-positive breast cancer [��].
Anot�er HIF in�ibitor� topotecan� is in clinical trial 
in advanced� refractory non-small cell lung cancer [��]. 
Trafalis et al. [�4] in P�ase II study investigated t�e 
efficacy and safety of DNA topoisome rase I in�ibitor 
irinotecan plus bevacizumab� a monoclonal antibody 
against VEGF �BEVIRI� in patients wit� relapsed c�e-
moresistant small cell lung cancer. BEVIRI combina-
tion in relapsed c�emoresistant small cell lung cancer 
demonstrates promising efficacy and low toxicity 
compared to �istorical controls [�4]. In NAPOLI-�� 
global� randomized P�ase III study evaluating nal-
IRI — a nanoliposomal irinotecan — wit� or wit�-
out fluorouracil and leucovorin in 4�7 patients wit� 
metastatic pancreatic cancer previously treated wit� 
gemcitabine-based t�erapy� overall survival benefit 
for nal-IRI plus fluorouracil and leucovorin over fluo-
rouracil and leucovorin wit� a similar safety profile �as 
been demonstrated [�5]. Combination c�emot�erapy 
wit� oral S-� and biweekly �4-�our infusions of irino-
tecan plus bevacizumab appears to be �ig�ly active 
and well tolerated bot� as first-line and second-line 
c�emot�erapy for metastatic colorectal cancer [��]. 
In�ibition of HIF-�α by PX-47� en�ances t�e anti-
tumor effect of gemcitabine by inducing immunogenic 
cell deat� in pancreatic ductal adenocarcinoma [�7].
In summary� blocking �ypoxia and HIF-� pat�way 
is beneficial in targeting solid cancers. Nevert�eless� 
t�ere �ave been several approved drugs t�at affect t�e 
HIF-�α pat�way and could serve as adjuvant t�erapy 
for certain types of cancers along wit� t�e existing 
treatments. Future developments would be directed 
towards t�e drugs t�at are more specific for HIF-� in-
�ibition [��].
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